Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. cut its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 2.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 6,044,750 shares of the specialty pharmaceutical company’s stock after selling 160,506 shares during the quarter. Vanguard Group Inc. owned about 10.78% of Supernus Pharmaceuticals worth $288,879,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. CWM LLC grew its stake in shares of Supernus Pharmaceuticals by 92.4% during the second quarter. CWM LLC now owns 3,080 shares of the specialty pharmaceutical company’s stock worth $97,000 after purchasing an additional 1,479 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in Supernus Pharmaceuticals by 8.8% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,375 shares of the specialty pharmaceutical company’s stock valued at $453,000 after purchasing an additional 1,161 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in Supernus Pharmaceuticals by 30.4% during the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 85,534 shares of the specialty pharmaceutical company’s stock worth $2,696,000 after purchasing an additional 19,949 shares in the last quarter. Castlekeep Investment Advisors LLC purchased a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter worth approximately $1,263,000. Finally, Ruffer LLP purchased a new stake in Supernus Pharmaceuticals in the third quarter valued at $2,647,000.

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock opened at $54.73 on Friday. Supernus Pharmaceuticals, Inc. has a 1 year low of $29.16 and a 1 year high of $59.68. The firm has a market cap of $3.14 billion, a PE ratio of -80.48, a price-to-earnings-growth ratio of 1.73 and a beta of 0.71. The firm’s 50-day simple moving average is $50.69 and its 200-day simple moving average is $48.30.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Craig Hallum set a $65.00 price objective on Supernus Pharmaceuticals in a research note on Wednesday. Zacks Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, Stifel Nicolaus raised their price objective on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research note on Friday, December 19th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $62.17.

Insider Buying and Selling

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 710 shares of the stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $44.44, for a total value of $31,552.40. Following the sale, the vice president directly owned 14,508 shares of the company’s stock, valued at $644,735.52. This trade represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bethany Sensenig sold 4,475 shares of the company’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $51.01, for a total transaction of $228,269.75. The SEC filing for this sale provides additional information. Insiders sold a total of 25,185 shares of company stock worth $1,268,022 in the last three months. 8.80% of the stock is owned by insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.